Literature DB >> 12076763

RSV entry inhibitors block F-protein mediated fusion with model membranes.

Vladimir Razinkov1, Clayton Huntley, George Ellestad, Girija Krishnamurthy.   

Abstract

RSV fusion is mediated by F-protein, a major viral surface glycoprotein. CL-309623, a specific inhibitor of RSV, interacts tightly with F-protein, which results in a hydrophobic environment at the binding site. The binding is selective for F-protein and does not occur with G-protein, a surface glycoprotein that facilitates the binding of RSV to target cells, or with lipid membranes at concentrations in the sub-millimolar range. Using an assay based on the relief of self-quenching of octadecyl rhodamine (R18) incorporated in the RSV envelope, we show that the virus fuses efficiently with large unilamellar vesicles containing cholesterol, in the absence of specific receptor analogs. Fusion of cp-52, a mutant virus lacking the G and SH surface glycoproteins, with vesicles is inhibited by CL-309623 and RFI-641 due to specific interactions of the inhibitor(s) with the fusion protein. Both virus-vesicle and virus-cell fusion are inhibited with equal potency. The formation of the binary complex of CL-309623 with F-protein in its native state, resulting in the inhibition of fusion and entry of virus, is a prerequisite for the observed anti-RSV activity in cell cultures.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12076763     DOI: 10.1016/s0166-3542(02)00050-5

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  10 in total

1.  Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.

Authors:  Asunción Mejías; Susana Chávez-Bueno; Ana María Ríos; Mónica Fonseca Aten; Brett Raynor; Estrella Peromingo; Perla Soni; Kurt D Olsen; Peter A Kiener; Ana María Gómez; Hasan S Jafri; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 2.  Pharmacologic advances in the treatment and prevention of respiratory syncytial virus.

Authors:  Kerry M Empey; R Stokes Peebles; Jay K Kolls
Journal:  Clin Infect Dis       Date:  2010-05-01       Impact factor: 9.079

Review 3.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

4.  Cholesterol-rich microdomains as docking platforms for respiratory syncytial virus in normal human bronchial epithelial cells.

Authors:  Homero San-Juan-Vergara; Viviana Sampayo-Escobar; Niradiz Reyes; Byeong Cha; Lisandro Pacheco-Lugo; Terianne Wong; Mark E Peeples; Peter L Collins; Maria Eugenia Castaño; Shyam S Mohapatra
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

5.  RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy.

Authors:  Rene Alvarez; Sayda Elbashir; Todd Borland; Ivanka Toudjarska; Philipp Hadwiger; Mathias John; Ingo Roehl; Svetlana Shulga Morskaya; Rick Martinello; Jeffrey Kahn; Mark Van Ranst; Ralph A Tripp; John P DeVincenzo; Rajendra Pandey; Martin Maier; Lubomir Nechev; Muthiah Manoharan; Victor Kotelianski; Rachel Meyers
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

6.  Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.

Authors:  Jeong-Joong Yoon; Mart Toots; Sujin Lee; Myung-Eun Lee; Barbara Ludeke; Jasmina M Luczo; Ketaki Ganti; Robert M Cox; Zachary M Sticher; Vindya Edpuganti; Deborah G Mitchell; Mark A Lockwood; Alexander A Kolykhalov; Alexander L Greninger; Martin L Moore; George R Painter; Anice C Lowen; Stephen M Tompkins; Rachel Fearns; Michael G Natchus; Richard K Plemper
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 7.  CDC42 Use in Viral Cell Entry Processes by RNA Viruses.

Authors:  Thomas Swaine; Matthias T Dittmar
Journal:  Viruses       Date:  2015-12-10       Impact factor: 5.048

Review 8.  Emerging drugs for respiratory syncytial virus infection.

Authors:  Wieslawa Olszewska; Peter Openshaw
Journal:  Expert Opin Emerg Drugs       Date:  2009-06       Impact factor: 4.191

9.  Profilin is required for viral morphogenesis, syncytium formation, and cell-specific stress fiber induction by respiratory syncytial virus.

Authors:  Vira Bitko; Anja Oldenburg; Nicolle E Garmon; Sailen Barik
Journal:  BMC Microbiol       Date:  2003-05-09       Impact factor: 3.605

Review 10.  Modulation of Host Immunity by Human Respiratory Syncytial Virus Virulence Factors: A Synergic Inhibition of Both Innate and Adaptive Immunity.

Authors:  Gisela Canedo-Marroquín; Orlando Acevedo-Acevedo; Emma Rey-Jurado; Juan M Saavedra; Margarita K Lay; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Front Cell Infect Microbiol       Date:  2017-08-16       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.